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An increase of serum creatine kinase (CK) has been observed in clinical studies of nitrogen-containing
aminobisphosphonates (N-BPs). Osteoclasts are thought to be the source of the CK, but there is no clear evidence for the
hypothesis. In this study, CK release from rabbit osteoclasts induced by N-BPs was examined in an in vitro culture system.
Rabbit bone-derived cells were cultured for 3 days on the N-BPs pretreated cortical bone slices. CK activity in the culture
medium was measured at 3 days of culture. The CK activity was increased with all N-BPs at concentrations at which showed
antiresorptive activity over 60% inhibition of C-terminal cross-linking telopeptide of type I collagen (CTX-1) release. The
maximum induction of CK activity was 2.6 times the control level. The lowest N-BP concentration inducing CK release was
3 times lower than that required to decrease the osteoclast number. Bafilomycin A1, an inhibitor of vacuolar H+-ATPase,
abrogated all N-BP actions, including CK release. Bone-derived cells except osteoclasts were insensitive to bafilomycin A1,
suggesting that osteoclasts were the source of CK. Regarding the time course, CK release occurred after a 1 day lag time
and increased steadily until day 3 of culture. These results show that CK release is induced by N-BPs from osteoclasts at
concentrations at which N-BPs show antiresorptive activity over 60% inhibition of CTX-1 release in vitro. These findings
explain the mechanism of the CK increase induced by clinical use of N-BPs.
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Creatine kinase (CK) is a dimeric enzyme of about 86 kDa
that catalyzes the reaction of creatine and adenosine triphos-
phate (ATP) to form phosphocreatine and adenosine di-
phosphate (ADP), a crucial reaction for cellular energy
generation and metabolism (Wallimann et al. 1992). The en-
zyme has three isoenzymes: ubiquitous brain-type creatine
kinase (CK-BB); sarcomeric muscle type (CK-MM) and car-
diac muscle type (CK-MB) (Eppenberger et al. 1967).
Mature osteoclasts are multinucleated, giant cells that
resorb bone based on synthesis and secretion of acid and
degradative enzymes (Teitelbaum 2007), and maintain a
high energy state for active bone resorption (Hazama et al.
2009). The CK-BB gene is highly expressed in rabbit oste-
oclasts (Sakai et al. 1995) and CK-BB is the predominant
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in any medium, provided the original work is pinduced osteoclastogenesis in mouse (Chen et al. 2010). In
immunohistochemical analysis, CK-BB expression in oste-
oclasts has been shown in bone sections (Sistermans et al.
1995). Moreover, decreasing CK-BB gene expression by
RNA interference or blocking of activity by cyclocreatine,
an inhibitor of CK-BB, suppresses bone resorption by os-
teoclasts grown in vitro (Chang et al. 2008). The blocking
was considered via effects on actin ring formation, RhoA
GTPase activity, and vacuolar H+-ATPase function. Fur-
thermore, CK-BB is present in serum in patients with
osteopetrosis and in some fetal and malignant tissues, and
abnormal osteoclasts may be a potential source of circu-
lating CK-BB in osteopetrosis (Yoneyama et al. 1989;
Whyte et al. 1996). Increases in tartrate-resistant acid
phosphatase (TRAP) and CK-BB in serum were occurred
in osteopetrosis (Waguespack et al. 2002).
Aminobisphosphonates (N-BPs) are widely used drugs
for treatment of osteoporosis because of their strong in-
hibition of accelerated bone resorption and the conse-
quent increase in bone mineral density and prevention ofn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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et al. 2009). Two phosphate side chains on the central car-
bon atom in the P–C–P backbone are mainly responsible
for binding to bone, with complementary interactions
through a hydroxyl group (Rogers 2003; Russell et al. 2008).
N-BPs also have a nitrogen-containing side chain on the
central carbon that determines the inhibitory potency for
a target enzyme in the mevalonate pathway, farnesyl pyro-
phosphate (FPP) synthase. Therefore, the side chains
determine the antiresorptive potency (Ebetino et al. 2011).
Bone-bound N-BPs are internalized by bone-resorbing oste-
oclasts and reduce the bone resorption activity or viability of
the cells through inhibition of FPP synthase. Release of
bone-bound N-BPs is promoted by vacuolar H+-ATPase,
which is localized along the ruffled borders of osteoclasts
and pumps protons out onto the bone surface, and this re-
lease can be inhibited by inhibitors of V-ATPase such as
bafilomycin A1 (Takami et al. 2003).
An increase in the serum CK level has been observed
in clinical studies of N-BPs. The frequency of CK eleva-
tion was between 1% and less 5% in a trial of 5 mg alen-
dronate (in Japanese package insert), while increases of
CK-BB and CK-MB were found in single and multiple
oral dose phase I studies of risedronate in Japanese
healthy adult male subjects (Ogura et al. 2004). Mino-
dronic acid treatment at 1 mg has been found to elevate
CK at a frequency of less 1% (in Japanese package in-
sert). Thus, many reports have shown CK elevation dur-
ing N-BP treatment, but the mechanism is unclear. We
hypothesized that CK is released from osteoclasts, but
not from other cells present in bone. To test this hy-
pothesis, we examined CK release induced by N-BPs
from rabbit bone-derived cells in vitro, and we assessed
the effect of bafilomycin A1 on CK release to determine
the source of CK. We also examined the time course of
CK release after treatment with N-BPs.
Materials and methods
Reagents
Alendronate and risedronate were purchased from LKT la-
boratories (St. Paul, MN, USA). Minodronic acid was sup-
plied by Astellas Pharma (Tokyo, Japan). Bafilomycin A1
was obtained from Wako Pure Chemical Industries (Osaka,
Japan). Reagents for TRAP staining were purchased from
Sigma Chemical (St. Louis, MO, USA). Alpha-modified
Eagle's medium (α-MEM) and fetal bovine serum (FBS)
were purchased from Gibco (Grand Island, NY, USA).
Preparation of osteoclast-containing bone cells
Unfractionated bone cells were isolated from femurs, tibias,
humeri, ulnas, and radii of 10-day-old Kbl:NZW rabbits
(Kitayama Labes, Nagano, Japan) using a reported method
(Kakudo et al. 1996) with minor modifications. Briefly, the
long bones of rabbits were minced for 10 min in α-MEMplus 5% FBS as culture medium, after soft connective tissues
were removed. Bone cells were dissociated from bone frag-
ments by vigorous vortexing for 1 min. After sedimentation
of the bone fragments for 2 min under normal gravity, a
supernatant containing the released cells was obtained. Bone
cells were collected by centrifugation twice at 40 g for 2 min.
The cells were prepared as 5 × 106 viable cells/mL. Animal
studies were conducted in compliance with the Guidelines
for Animal Studies established by Research Headquarters,
Ono Pharmaceutical Co., Ltd (Osaka, Japan).
Cortical bovine bone slices
Cortical bone slices were cut from bone sticks prepared
from bovine femoral cortical bone. The sticks were cut
into slices of thickness 0.15 mm using an Isomet low
speed saw (Buehler, Lake Bluff, IL, USA). The bone slices
had a 6-mm diameter for fitting into 96-well plates. The
slices were sterilized in 70% ethanol and pre-incubated in
culture medium. The surface area of each cortical bone
slice was calculated as 59.3 mm2.
Treatment of cortical bone slices with N-BPs
Bone slices were treated for 19 h with 150 μL culture
medium containing alendronate (3–30 μmol/L), risedro-
nate (1–10 μmol/L), or minodronic acid (0.3–3 μmol/L).
Pit formation assay
Culture medium (100 μL) containing bone cells (5 × 105)
was added onto cortical bone slices pre-treated with N-
BPs. These slices had previously been soaked in 50 μL of
culture medium in a 96-well plate. After incubation in a
CO2 incubator (5% CO2, 95% air) at 37°C for 2 h, the
150 μl of culture medium was replaced with fresh cul-
ture medium and incubated for 3 more days. In experi-
ments using bafilomycin A1, the culture medium was
refreshed with or without bafilomycin A1 (10 nmol/L).
In the time course study, the culture medium was chan-
ged to fresh medium every day, except in the whole
treatment (0–3 days) group.
Creatine kinase assay
CK activity was measured with a CK Test Wako (Wako
Pure Chemical Industries Ltd., Osaka, Japan). Each CK ac-
tivity was calculated by subtracting the background in cul-
ture medium and bone slices. One unit was defined as the
amount of enzyme that catalyzed reaction of 1 μmol/L sub-
strate in 1 min at 37°C.
Measurement of bone resorption
Bone resorption was measured based on release of C-
terminal cross-linking telopeptide of type I collagen (CTX-
1) during culture. The CTX-I level in culture supernatant
was determined using a CrossLaps for Culture kit (Nordic
Bioscience Diagnostics A/S, Herlev, Denmark) with samples
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tracting the background in culture medium, bone slices
and bone-derived cells.
Measurement of osteoclast number
TRAP staining was used for osteoclast quantification.
Briefly, osteoclasts were fixed for 1 h by soaking bone slices
in 4% paraformaldehyde solution. After washing with phos-
phate buffered saline (PBS (-)) and PBS (-) with 0.1% Triton
X-100, osteoclasts were stained by incubation with naph-
thol AS-BI phosphate in dimethylformamide in acetate-
tartrate buffer for 10 min at 37°C. Osteoclasts numbers
were quantified as the number of TRAP-positive multinu-
clear cells on bone slices. TRAP-stained osteoclasts in bone
slices were counted using an upright microscope (Olympus,
Tokyo, Japan) under blinded conditions.
Statistics
All data are presented as means ± SE. Statistical analyses
were performed using SAS System Release 6.10 or above.
In the bafilomycin A1 untreated experiment, differences
between control and treated group in each N-BP were an-
alyzed by Williams test. In the bafilomycin A1 treated ex-
periment, differences between groups, minodronic acid
treated groups and control group without or with bafilo-
mycin A1, were analyzed by Tukey test, except for use of
a Steel-Dwass test for osteoclast number. Differences were
considered significant at p < 0.05.
Results
Effects of N-BPs on bone resorption and CK release in a
rabbit pit assay
The CTX-1 level, an index of bone resorption activity, and
CK release were measured in an in vitro rabbit bone-derived
cell culture on cortical bone slices pretreated with three
N-BPs. The concentrations of alendronate (3–30 μmol/L),Table 1 Effects of aminobisphosphonates on bone resorption
Treatment









Minodronic acid 0.3 6
1 2
3 6
Values represents the mean ± SE of 8 individual cultures.
#Significantly different from control group (p < 0.05).risedronate (1–10 μmol/L) and minodronic acid (0.3–
3 μmol/L) were selected based on study showing roughly
50% CTX-1 inhibition at the lowest N-BP concentrations
(Halasy-Nagy et al. 2001; Nozaki et al. 2008). Each N-BP
dose-dependently decreased the CTX-1 level (Table 1).
Over 50% inhibition of CTX-1 level was achieved by
10 μmol/L of alendronate, ≤1 μmol/L of risedronate
and ≤0.3 μmol/L of minodronic acid. Inhibitory ratios of
minodronic acid on CTX-1 level were higher than that of
risedronate at both 1 and 3 μmol/L. Consequently, the
most potent antiresorptive N-BPs in the test was mino-
dronic acid, followed in order by risedronate and alendro-
nate. Each N-BP also dose-dependently increased CK
release. A maximum CK release, rose up to 2.6 times the
control level, was occurred at the highest concentration of
minodronic acid. Significant CK release was occurred all
tested N-BPs at concentrations giving over 60% inhibition
of CTX-1 level.Effects of bafilomycin A1 with minodronic acid in a
rabbit pit assay
The effect of bafilomycin A1 on the CTX-1 level, CK
activity and osteoclast number in cultured bone-derived
cells were examined to clarify the source of CK release
as osteoclasts. In the absence of bafilomycin A1, minodronic
acid dose-dependently decreased the CTX-1 level (Table 2).
The CTX-1 release was completely abolished by addition of
bafilomycin A1 into the culture. Minodronic acid dose-
dependently increased the CK activity, and the increased
CK activity was also cancelled by bafilomycin A1 addition
(Figure 1). Furthermore, minodronic acid reduced TRAP
positive osteoclast number at 1 μmol/L or more (Figure 2).
The decrease in osteoclast number by minodronic acid was
completely abolished by addition of bafilomycin A1 into the
culture.and CK activities in rabbit bone cells culture
TX-1 CK activity
(U/L)oncentration (nmol/L) % Inhibition
01.1 ± 8.5 - 9.7 ± 0.3
35.1 ± 6.5 32.8 10.0 ± 0.2
8.1 ± 6.0 71.1 12.2 ± 0.4#
5.8 ± 1.4 87.2 13.3 ± 0.6#
9.4 ± 5.9 55.5 10.8 ± 0.4
7.5 ± 3.8 81.4 12.6 ± 0.2#
7.4 ± 2.2 91.3 16.4 ± 0.6#
1.8 ± 4.0 69.3 15.9 ± 0.8#
5.8 ± 4.6 87.2 22.5 ± 1.4#
.5 ± 1.0 96.8 25.0 ± 0.7#





Without bafilomycin A1 With bafilomycin A1
Control - 265.0 ± 19.2 3.0 ± 0.6*
Minodronic acid 0.3 50.9 ± 4.3# 3.2 ± 0.4*
1 14.0 ± 1.4# 2.4 ± 0.5*
3 6.2 ± 1.1# 2.5 ± 0.3*
Values represents the mean ± SE of 10 individual cultures.
#Significantly different from bafilomycin A1 untreated control (p < 0.05).
*Significantly different from corresponding bafilomycin A1 untreated group (p < 0.05).
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a rabbit pit assay
The time course of CK release was analyzed in bone-
derived cell culture with minodronic acid treatment. CK
activities were measured in culture mediums obtained
on days 0–1, 1–2, 1–3, and 0–3 (Figure 3). CK activity
was not increased during day 0–1, but was increased
minodronic acid treatment during days 1–2 and 2–3.
Discussion
The most potent antiresorptive N-BPs in the test was
minodronic acid, followed in order by risedronate and
alendronate. These findings are similar to the order of po-
tency for inhibition of FPP synthase (Dunford et al. 2001;
Ohno et al. 2011) and effects in rabbit osteoclast cultures
(Halasy-Nagy et al. 2001; Nozaki et al. 2008). Contrary to
N-BPs have different hydroxyapatite binding affinities
(Ebetino et al. 2011), antiresorptive potency on bone slices



















Figure 1 Effects of minodronic acid and bafilomycin A1 on CK activity
SE of 10 individual cultures. #:Significantly different between control and m
(p < 0.05). *:Significantly different between corresponding bafilomycin A1 trsuggests that the influence on binding affinities to hy-
droxyapatite may be smaller than difference of antiresorp-
tive activities. Despite there is difference on antiresorptive
potency in N-BPs, the minimum concentration for induc-
tion of CK release was approximately that required over
60% inhibition of CTX-1 release for all three N-BPs.
Ito et al. found that CK release was induced by 3 mmol/L
incadronate, but not by alendronate, in a rabbit osteoclast
culture on a plastic plate (Ito et al. 1998). In contrast, CK
was released in culture with 10–30 μmol/L of alendronate
in this study. We and others have shown antiresorptive
activity at 3–30 μmol/L alendronate in rabbit osteoclasts
cultured on bovine cortical bone slices (Halasy-Nagy et al.
2001). The concentration of alendronate required for antire-
sorptive action and CK release on bone slices was 1000
times lower than that used by Ito et al., the culture condition
of the osteoclasts may cause significant difference of results.
The decrease in osteoclast number occurred at 1 μmol/L,





in rabbit bone-derived cells. Each column represents the mean ±
inodronic acid treated groups in bafilomycin A1 untreated condition




















Figure 2 Effects of minodronic acid and bafilomycin A1 on osteoclast number in rabbit bone-derived cells. Each column represents the
mean ± SE of 10 individual cultures. #:Significantly different between control and minodronic acid treated groups in bafilomycin A1 untreated
condition (p < 0.05). *:Significantly different between corresponding bafilomycin A1 treated and untreated groups (p < 0.05).
Tanaka et al. SpringerPlus  (2015) 4:59 Page 5 of 7rabbit pit assay is 0.11 μmol/L (Nozaki et al. 2008); there-
fore, the concentration of minodronic acid required to de-
crease the osteoclast number was roughly 10 times higher
than the IC50 for CTX-1 release. The alendronate and rise-




















Figure 3 Time course study of CK release from rabbit bone-derived c
the mean ± SE of 6 individual culture of indicated incubation periods. #:Sig
groups within corresponding incubation period (p < 0.05).number were also roughly 10 times higher than the respect-
ive IC50 values for CTX-1 release (Halasy-Nagy et al. 2001).
These results suggest that the dose ratios for antiresorptive









ells after treatment with minodronic acid. Each column represents
nificantly different between control and minodronic acid treated
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N-BPs occurs via prenylation of small G proteins like Rab
(Nishida et al. 2003; Coxon et al. 2001), while that for
apoptosis involves extracellular signal-regulated kinase
(ERK) and Bim, Bcl-2 homology 3 (BH3)-only protein (the
ERK/Bim axis) (Matsumoto et al. 2011). The CK release is
related to cellular damage such as that due to apoptosis, but
the N-BPs concentration for CK release was 0.3 μmol/L for
minodronic acid, which is 3 times lower than that required
for a decrease of osteoclast number. However, histological
changes related to osteoclasts apoptosis was observed at
0.1 μmol/L of minodronic acid (Additional file 1). Since the
decrease in osteoclast number is considered to be a conse-
quence of osteoclast apoptosis (Ito et al. 1999), the param-
eter may be less sensitive for cellular damage and thus a
high concentration of N-BPs is needed to decrease the
osteoclast number. CK release from osteoclasts also had a 1-
day lag time and occurred during days 1 to 3 of culture, with
a maximum from days 2 to days 3. Morphological changes
of osteoclasts are sequential, with initial actin ring disruption
related to an antiresorptive effect within 1 day after treat-
ment, and subsequent nuclear condensation after an ap-
proximately 1-day lag time, with maximum apoptosis on
day 3 (Halasy-Nagy et al. 2001; Tsubaki et al. 2013). Hence,
all examined N-BPs induced CK release at micromolar to
tens of micromolar concentrations in association with osteo-
clast apoptosis and bone resorption. The 1-day lag time and
maximum response on day 3 (as N-BPs induced apoptosis)
indicates that CK release is an osteoclast apoptosis-related
event.
Mature osteoclasts create an isolated microenvironment
between themselves and the bone surface, into which the
cells secrete protons via vacuolar H+-ATPase and the lyso-
somal protease cathepsin K. Bone-bound N-BPs are eluted
by acid during bone resorption and may be incorporated
into osteoclasts, and osteoclasts-incorporate N-BPs show
antiresorptive activity and cause apoptosis. All pharmaco-
logical action of minodronic acid, inhibition of CTX-1 re-
lease, reduction of osteoclast number and CK release were
abrogated by the V-ATPase inhibitor bafilomycin A1. The
antiresorptive action and CK release induced by alendro-
nate and risedronate were also eliminated by bafilomycin
A1 (data not shown). Because acid release from osteo-
clasts was inhibited by bafilomycin A1, N-BPs were not
released from bone slices and not incorporated into osteo-
clasts in bafilomycin A1 treated condition. Besides osteo-
clasts, stromal cells and bone marrow cells were present
in the culture system, but these cells are not sensitive to
bafilomycin A1. Bafilomycin A1 also blocked vesicle
trafficking with sufficient inhibition at approximately
50 nmol/L or more, but the effect was minimal at our used
condition around 10 nmol/L (Johnson et al. 1993). In
addition, Sistermans et al. reported no CK-BB was found in
both osteocyte and cartilage, and general CK-BB expressionin bone was negative (Sistermans et al. 1995). Therefore,
these results suggest that CK is released from osteoclasts via
the pharmacological effect of N-BPs. We did not identify
CK isoenzymes because of the limited CK activity, and this
is a limitation of the study. However, expression of CK ex-
cept CK-BB was tissue specific. The ubiquitous CK-BB is
strongly expressed in osteoclasts and it is likely that CK-BB
was released from damaged osteoclasts into extracellular
fluid due to N-BP treatment. The serum CK level increases
in some patients treated with N-BPs and serum CK-BB
might be a useful marker for osteoclast damage in N-BP
treatment.
Regarding the CK-BB and ATP axis, the importance of
ATP function in osteoclasts and osteoblasts is becoming
clearer. Intracellular ATP levels play a pivotal role in
osteoclast apoptosis and in the bone-resorbing function
of osteoclasts (Miyazaki et al. 2012). In phagocytes, local
cytoskeletal dynamics during cell motility is coupled to
onsite availability of ATP generated by CK-BB (Kuiper
et al. 2008). Therefore, CK-BB and ATP are important in
osteoclast bone resorption. N-BP-induced damage in os-
teoclasts may cause extracellular release of a high con-
centration of ATP. Osteoclasts and osteoblasts express
various members of the P2 receptor family, for which
ATP is a physiological ligand (Burnstock et al. 2013).
Moreover, P2 receptors are involved in osteoclast fusion
(Pellegatti et al. 2011) and P2x receptors may negatively
regulate bone mineralization in osteoblasts (Orriss et al.
2012). Thus, a high concentration of ATP from damaged
osteoclasts might underlie N-BPs induced giant osteo-
clast formation (Weinstein et al. 2009), and might influ-
ence on cross-talk between osteoblasts and osteoclasts.
Conclusion
N-BPs induced CK release at an antiresorptive activity over
60% inhibition of CTX-1 in in vitro culture. The CK release
was considered to be derived from osteoclasts, because it
had a 1 day lag time and was blocked by bafilomycin A1.
These findings support the possible mechanism of CK ele-
vation by N-BPs in the clinic.
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Additional file 1: Induction of Creatine Kinase Release from
Cultured Osteoclasts via the Pharmacological Action of
Aminobisphosphonates.
Competing interests
All authors are employees of Ono Pharmaceutical Co., Ltd., the sponsor of
the study.
Authors’ contributions
MT, HM and RK designed study and collected the data. MT drafted the
manuscript. KK contributed project development and manuscript editing. All
authors read and approved the final manuscript.
Tanaka et al. SpringerPlus  (2015) 4:59 Page 7 of 7Acknowledgments
We thank Drs. Akihiro Hosoya and Hidehiro Ozawa for their excellent support
in the histological work.
Author details
1Research Promotion, Ono Pharmaceutical Co., Ltd, 3-1-1, Sakurai,
Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan. 2Discovery Research
Laboratories, Ono Pharmaceutical Co., Ltd, Shimamoto-cho, Mishima-gun,
Osaka 618-8585, Japan.
Received: 20 October 2014 Accepted: 22 January 2015References
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC,
Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE
(1996) Randomised trial of effect of alendronate on risk of fracture in women with
existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet
348(9041):1535–1541
Burnstock G, Arnett TR, Orriss IR (2013) Purinergic signalling in the
musculoskeletal system. Purinergic Signal 9(4):541–572
Chang EJ, Ha J, Oerlemans F, Lee YJ, Lee SW, Ryu J, Kim HJ, Lee Y, Kim HM,
Choi JY, Kim JY, Shin CS, Pak YK, Tanaka S, Wieringa B, Lee ZH, Kim HH (2008)
Brain-type creatine kinase has a crucial role in osteoclast-mediated bone
resorption. Nat Med 14(9):966–972
Chen J, Sun Y, Mao X, Liu Q, Wu H, Chen Y (2010) RANKL up-regulates brain-type
creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis.
J Biol Chem 285(47):36315–36321
Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon
AD, Nesbitt SA, Horton MA, Seabra MC, Ebetino FH, Rogers MJ (2001)
Identification of a novel phosphonocarboxylate inhibitor of Rab
geranylgeranyl transferase that specifically prevents Rab prenylation in
osteoclasts and macrophages. J Biol Chem 276(51):48213–48222
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino
FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl
diphosphate synthase in vitro and inhibition of bone resorption in vivo by
nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296(2):235–242
Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA,
Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA,
McKenna CE, Russell RG (2011) The re lationship between the chemistry and
biological activity of the bisphosphonates. Bone 49(1):20–33
Eppenberger HM, Dawson DM, Kaplan NO (1967) The comparative enzymology
of creatine kinases. I. Isolation and characterization from chicken and rabbit
tissues. J Biol Chem 242(2):204–209
Halasy-Nagy JM, Rodan GA, Reszka AA (2001) Inhibition of bone resorption by
alendronate and risedronate does not require osteoclast apoptosis.
Bone 29(6):553–559
Hazama R, Qu X, Yokoyama K, Tanaka C, Kinoshita E, He J, Takahashi S, Tohyama K,
Yamamura H, Tohyama Y (2009) ATP-induced osteoclast function: the formation of
sealing-zone like structure and the secretion of lytic granules via microtubule-
deacetylation under the control of Syk. Genes Cells 14(7):871–884
Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, Kiyoki M (1998)
Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo.
Calcif Tissue Int 63(2):143–147
Ito M, Amizuka N, Nakajima T, Ozawa H (1999) Ultrastructural and cytochemical
studies on cell death of osteoclasts induced by bisphosphonate treatment.
Bone 25(4):447–452
Johnson LS, Dunn KW, Pytowski B, McGraw TE (1993) Endosome acidification and
receptor trafficking: bafilomycin A1 slows receptor externalization by a mechanism
involving the receptor's internalization motif. Mol Biol Cell 4(12):1251–1266
Kakudo S, Miyazawa K, Kameda T, Mano H, Mori Y, Yuasa T, Nakamura Y,
Shiokawa M, Nagahira K, Tokunaga S, Hakeda Y, Kumegawa M (1996)
Isolation of highly enriched rabbit osteoclasts from collagen gels: A new
assay system for bone-resorbing activity of mature osteoclasts. J Bone Miner
Metab 14(3):129–136, doi:10.1007/BF02239480
Kuiper JW, Pluk H, Oerlemans F, van Leeuwen FN, de Lange F, Fransen J,
Wieringa B (2008) Creatine kinase-mediated ATP supply fuels actin-based
events in phagocytosis. PLoS Biol 6(3):e51
Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y,
Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures inJapanese postmenopausal women with established osteoporosis: a randomized
placebo-controlled double-blind study. Osteoporos Int 20(8):1429–1437
Matsumoto T, Nagase Y, Iwasawa M, Yasui T, Masuda H, Kadono Y, Nakamura K,
Tanaka S (2011) Distinguishing the proapoptotic and antiresorptive functions
of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/
Bim axis. Arthritis Rheum 63(12):3908–3917
Miyazaki T, Iwasawa M, Nakashima T, Mori S, Shigemoto K, Nakamura H, Katagiri
H, Takayanagi H, Tanaka S (2012) Intracellular and extracellular ATP
coordinately regulate the inverse correlation between osteoclast survival and
bone resorption. J Biol Chem 287(45):37808–37823
Nishida S, Kikuichi S, Haga H, Yoshioka S, Tsubaki M, Fujii K, Irimajiri K (2003)
Apoptosis-inducing effect of a new bisphosphonate, YM529, on various
hematopoietic tumor cell lines. Biol Pharm Bull 26(1):96–100
Nozaki K, Mori M, Chono K, Tanaka S, Fukushima S, Sasamata M, Kayasuga R, Mori
H, Tanaka M, Kawabata K (2008) Mechanism of pharmacologic action of
minodronic acid. (in Japanes). Clin Pharmacol Ther 18:S7–S18
Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese
volunteers: single and multiple oral dose studies. J Bone Miner Metab 22(2):111–119
Ohno K, Mori K, Orita M, Takeuchi M (2011) Computational insights into binding of
bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem 18(2):220–233
Orriss IR, Key ML, Brandao-Burch A, Patel JJ, Burnstock G, Arnett TR (2012) The
regulation of osteoblast function and bone mineralisation by extracellular
nucleotides: The role of p2x receptors. Bone 51(3):389–400
Pellegatti P, Falzoni S, Donvito G, Lemaire I, Di Virgilio F (2011) P2X7 receptor
drives osteoclast fusion by increasing the extracellular adenosine
concentration. FASEB J 25(4):1264–1274
Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen
D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of
risedronate on vertebral fractures in women with established postmenopausal
osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Osteoporos Int 11(1):83–91
Rogers MJ (2003) New insights into the molecular mechanisms of action of
bisphosphonates. Curr Pharm Des 9(32):2643–2658
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of
bisphosphonates: similarities and differences and their potential influence on
clinical efficacy. Osteoporos Int 19(6):733–759
Sakai D, Tong HS, Minkin C (1995) Osteoclast molecular phenotyping by random
cDNA sequencing. Bone 17(2):111–119
Sistermans EA, de Kok YJ, Peters W, Ginsel LA, Jap PH, Wieringa B (1995) Tissue- and
cell-specific distribution of creatine kinase B: a new and highly specific monoclonal
antibody for use in immunohistochemistry. Cell Tissue Res 280(2):435–446
Takami M, Suda K, Sahara T, Itoh K, Nagai K, Sasaki T, Udagawa N, Takahashi N
(2003) Involvement of vacuolar H+ -ATPase in incorporation of risedronate
into osteoclasts. Bone 32(4):341–349
Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J
Pathol 170(2):427–435
Tsubaki M, Itoh T, Satou T, Imano M, Komai M, Ogawa N, Mukai J, Nishida S (2013)
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor
cells via inhibition of Ras signaling pathways and Bim-mediated activation of the
intrinsic apoptotic pathway. Biochem Pharmacol 85(2):163–172
Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ (2002) Measurement
of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine
kinase accurately diagnoses type II autosomal dominant osteopetrosis but
does not identify gene carriers. J Clin Endocrinol Metab 87(5):2212–2217
Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM (1992) Intracellular
compartmentation, structure and function of creatine kinase isoenzymes in
tissues with high and fluctuating energy demands: the 'phosphocreatine
circuit' for cellular energy homeostasis. Biochem J 281(Pt 1):21–40
Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and
long-term oral bisphosphonate therapy. N Engl J Med 360(1):53–62
Whyte MP, Chines A, Silva DP, Landt Y, Ladenson JH (1996) Creatine kinase brain
isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among
the sclerosing bone disorders. J Bone Miner Res 11(10):1438–1443
Yoneyama T, Fowler HL, Pendleton JW, Sforza PP, Lui CY, Iranmanesh A, Gerard
RD (1989) Elevated levels of creatine kinase BB isoenzyme in three patients
with adult osteopetrosis. N Engl J Med 320(19):1284–1285
